About Us
Zydus Lifesciences is a global, innovation-driven lifesciences company committed to advancing scientific research and developing transformative healthcare solutions. With a focus on addressing unmet medical needs, the Company strives to improve quality of life through prevention, early diagnosis and effective disease management.
Zydus’ integrated operations encompass research and development, manufacturing, marketing and distribution, supported by advanced technology platforms and strong scientific capabilities. The Company has a diversified portfolio spanning generics, branded generics, specialty formulations, biosimilars, vaccines and active pharmaceutical ingredients (APIs). It has also strengthened its capabilities in biologics and biosimilars contract manufacturing, expanding its presence in next-generation therapies.
Serving patients across regulated and emerging markets, Zydus addresses critical therapeutic needs through its scientific expertise, manufacturing excellence and commitment to innovation. Its robust pipeline of novel drug discoveries reflects a continued focus on pioneering research and developing pathbreaking therapies that can make a meaningful difference to patients worldwide.
With innovation at the core of its long-term strategy, Zydus continues to explore new frontiers in lifesciences, expand access to quality healthcare and unlock new possibilities for better health outcomes, while driving sustainable growth and long-term value creation for stakeholders.
Seven Decades of
Legacy, Trust and
Innovation
0
Legacy Years
0
Employees Globally
0
R&D Scientists
0
Manufacturing Facilities
0
R&D Centres
0
Generic company in the US in terms of
prescriptions
Zydus’ journey of many firsts
Lipaglyn® (Saroglitazar)
India’s first indigenously discovered New Chemical Entity and the world’s first approved Glitazar – a pathbreaking therapy for diabetic dyslipidaemia.
Adalimumab (Exemptia®)
World’s first biosimilar of Adalimumab in India — expanding access to biologics for autoimmune diseases
TwinRab™
World’s first novel biological entity for rabies prophylaxis – an innovative monoclonal antibody cocktail developed for rabies post-exposure prophylaxis.
Ujvira (Trastuzumab Emtansine biosimilar)
World’s first biosimilar Antibody Drug Conjugate (ADC) – a breakthrough therapy for the treatment of early and advanced HER2-positive breast cancer.
Oxemia™ (Desidustat)
India’s first oral HIF-PH inhibitor for anaemia in chronic kidney disease – a novel therapy offering an alternative to injectable treatment options.
VaxiFlu4
India’s first trivalent inactivated influenza vaccine – designed to provide broader protection against influenza virus strains.
Tishtha™ (Nivolumab biosimilar)
World’s first biosimilar of Nivolumab – expanding access to advanced immuno-oncology treatment for multiple cancers.
Usnoflast
First-in-class novel oral NLRP3 inhibitor from Zydus – currently under clinical development for inflammatory and neurodegenerative diseases such as ALS, Parkinson’s disease, CAPS and ulcerative colitis.
Our Mission
Be a global life-sciences company transforming lives through pathbreaking discoveries.
Our Vision
To unlock new possibilities in life-sciences through quality healthcare solutions that impact lives.
Our Purpose
Empower people with the freedom to live healthier and more fulfilled lives.
Core Behaviours
Zydus First
Putting organisation before self
Excellence in execution
Being action-oriented
Adaptability to change
Keeping pace with change
Innovation
Being innovative in all that we do
Team & Collaboration
We not ‘I’
Respect, Trust & Integrity
Doing the right things, in the right way at the right time